Clinical Perspectives

Second-Line Therapy for Large B-Cell Lymphoma

In a recent article published in The New England Journal of Medicine hematologist Dr. Fred Locke at Moffitt Cancer Center details this international,...

Promises of Cell Therapy Bring Opportunities for Collaboration and Clinical Excellence

Finding ways to act on discrete targets on or within cancerous cells without affecting healthy cells is a key focus of several Moffitt research...

The Latest Research in Head and Neck-Endocrine Cancer Treatment

The Head and Neck-Endocrine Oncology Program joined in an engaging conversation exploring the latest research in cancer treatment. Learn more here.

Advanced Renal Cell Carcinoma Patients Sought for Autologous Dendritic Cell Immunotherapy Clinical Trial

Moffitt is recruiting adult patients with advanced renal cell carcinoma (RCC) scheduled or soon-to-be-scheduled to receive a nephrectomy or a biopsy...

Moffitt Researchers Lead Study Identified ctDNA for the Treatment of High-Risk Urothelial Carcinoma

Our Genitourinary Oncology department at Moffitt Cancer Center conducted a study using circulating tumor DNA to refine staging for high-risk upper...

Q&A: Dr. Agosto Shares Her Role as an Endocrine Oncologist

Salimar Agosto Salgado, MD, an associate member of the Department of Head and Neck-Endocrine Oncology, shares her experience as a dually trained...

Dr. Vogelbaum Leads the Development of the National Guidelines for Metastatic Brain Tumor Treatment

A multidisciplinary panel of experts, including Dr. Michael Vogelbaum, collaborated in a highly-structured guideline development process to address...

U.S. House Passes HPV Cancer Legislation

The United States House of Representatives recently passed the PREVENT HPV Cancers Act by voice vote. Anna Giuliano, PhD, director of Moffitt's...

Cancer Immunotherapy Breakthrough: Dendritic Cell Vaccines

The latest addition to oncotherapy is the use of dendritic cell (DC) vaccine therapy. Dendritic cell vaccine is a cross between a vaccine and a cell...

Hyperthermic Intraperitoneal Chemotherapy: Benefits of the Procedure for Peritoneal Disease Explained

Sean Dineen, MD, an associate member of the Department of Gastrointestinal Oncology describes what peritoneal disease is, and shares insight from his...

mRNA Vaccine Technology Being Studied for Head Neck Cancer

The success of the COVID-19 vaccine took mRNA technology from the laboratory to the spotlight, and Moffitt researchers are now part of a...

Novel Immunotherapy Trial using Chimeric Antigen Receptor Therapy (CAR T) for Relapsed Epithelial Ovarian Cancer

Dr. Robert M. Wenham, chair of Moffitt’s Department of Gynecologic Oncology, is leading the CAR T clinical trial designed to treat women with...

Understanding the Effects of the COVID Vaccine on Cancer Patients

To help better understand the effects of the COVID vaccine on cancer patients, Moffitt Cancer Center launched a study following patients before and...

A new type of CAR T called UltraCAR-T™ potentially a therapy for myeloid malignancies

A phase 1b study that was presented at the 2021 American Society of Hematology annual meeting looks at the safety and efficacy of a new type of CAR T...

Predicting Outcomes to Immunotherapy for NSCLC

There is an urgent need to identify biomarkers that can predict which patients will not respond to therapy and administer potential beneficial drugs...